TY - JOUR
T1 - Impact of genomics on personalized cancer medicine
AU - Arteaga, Carlos L.
AU - Baselga, José
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Recent advances in tumor genetics and drug development have led to the generation of a wealth of anticancer targeted therapies. A few recent examples indicate that these drugs are mainly, if not exclusively, active against tumors of a particular genotype that can be identified by a diagnostic test, usually by detecting a somatic alteration in the tumor DNA. However, for the majority of targeted therapies in development, there are still no clinical tools to determine which patients are most likely to benefit or, alternatively, be resistant de novo to these novel agents or drug combinations.
AB - Recent advances in tumor genetics and drug development have led to the generation of a wealth of anticancer targeted therapies. A few recent examples indicate that these drugs are mainly, if not exclusively, active against tumors of a particular genotype that can be identified by a diagnostic test, usually by detecting a somatic alteration in the tumor DNA. However, for the majority of targeted therapies in development, there are still no clinical tools to determine which patients are most likely to benefit or, alternatively, be resistant de novo to these novel agents or drug combinations.
UR - http://www.scopus.com/inward/record.url?scp=84856528286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856528286&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-11-2019
DO - 10.1158/1078-0432.CCR-11-2019
M3 - Article
C2 - 22298893
AN - SCOPUS:84856528286
SN - 1078-0432
VL - 18
SP - 612
EP - 618
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -